Kathryn Lurain

17PUBLICATIONS
127CO-AUTHORS
Development cooperationSocial determinants of healthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Social program evaluationCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 01, 2026
KSHV-infected endothelial cells expand and up-regulate angiogenic pathways and CXCR4 in patient-derived Kaposi sarcoma models.

|Mar 18, 2026
Kaposi sarcoma herpesvirus (KSHV) subtypes and impact on outcomes in KSHV-associated diseases.

Jose Mercado Matos, Vickie A Marshall, Elena M Cornejo Castro

|Mar 17, 2026
Tocilizumab as stabilizing frontline treatment in suspected KSHV inflammatory cytokine syndrome.

Kurtis Matthew Host, Christoph Weigel, Haley Lynn Klimaszewski

|Aug 05, 2025
Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.

Ramya Ramaswami, Kathryn Lurain, Mark N Polizzotto

|Feb 06, 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.

Ramya Ramaswami, Angela Shaulov Kask, Leonard D'Amico

|Jan 15, 2025
Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma.

Kathryn Lurain, Ramya Ramaswami, Eric Oksenhendler

Pageof 3

Frequent Collaborators

12 joint publications

Ramya Ramaswami

8 joint publications

Robert Yarchoan

6 joint publications

Thomas S Uldrick

3 joint publications

Elad Sharon